Replies to post #71996 on Biotech Values

[DewDiligence]

RPRX – I agree with your post on all counts except this one:

The problem though is not the drop out number, but the fact RPRX is keeping mum. Skeletons.

In my opinion, the high dropout rate could well be a problem in its own right—over and above the problems inherent in the disingenuous press release and the selective disclosure.